Supplementary Information

SUPPLEMENTARY INFROMATION

SI1. Dose deciding pilot study

As shown in Fig. S2, the test compounds (13, 17 and 70) were unable to induce significant effects in MWM test at an equivalent dose corresponding to donepezil (5 mg/kg, p.o.) i.e. the results obtained as escape latency time (ELT) and platform area crossings in MWM test were not significant. Later, the compounds (13, 17 and 70) were evaluated at relatively higher dose (10 mg/kg, p.o.) where they showed significant improvement of scopolamine-induced impaired spatial learning and memory in MWM test (Fig. 2). The dose (10 mg/kg, p.o.) was then continued for further *in vivo* experiments. Thus the dose of 13, 17 and 70 has been decided on the basis of this study.




Fig. S1: Test compounds (13, 17 and 70) did not significantly improve spatial learning and memory impairment in scopolamine induced amnesic mice in MWM test at 5 mg/kg, p.o. dose. Scopolamine treatment (1.4 mg/kg, i.p.) increased the ELT during probe trial sessions (A), and reduced the number of platform area crossings (B) as compared to the vehicle-treated control mice. Donepezil (5 mg/kg, p.o.) significantly shortened ELT (A) and increased number of platform area crossings (B) as compared to the scopolamine-treated control group. Compounds (13, 17 and 70) did not significantly improve the spatial learning and memory impairment (A, B) in MWM test at relatively lower dose (5 mg/kg, p.o.). Data are expressed as mean \pm SEM (n=6). ### p<0.001, ## p<0.01 vs. vehicle-treated control group. *** p<0.001, ** p<0.01, vs. scopolamine-treated control group.

Supplementary Information

SI2. In vitro blood-brain barrier permeation assay

Commercial drugs	Reported value ^a	Experimental value ^b
Diazepam	16	21.2±1.8
Verapamil	13	15.1±1.2
Progesterone	9.3	12.2±1.1
Clonidine	6.2	9.4±0.4
Corticosterone	5.1	8.2±0.5
Lomefloxacin	1.1	2.3±0.2
Ofoxacin	0.8	1.5±0.3
Atenolol	0.8	3.2±0.4
Dopamine	0.2	$1.8{\pm}0.2$

Table S1: Permeability ($P_e \ 10^{-6} \text{ cm/s}$) of nine commercial quality standards in the PAMPA-BBB assay.

^aTaken from reference [1]. ^bDetermined using PAMPA-BBB assay. Data are expressed as mean ± SEM of three independent experiments.




Fig S2: Linear correlation between experimental and reported permeability values of nine commercial drugs in the PAMPA-BBB assay. $P_e(\text{Exp.}) = 1.171 P_e(\text{Ref.}) + 1.489 (\text{R}^2 = 0.983)$

Supplementary Information

Table S2: Ranges of permeability (P_e , 10⁻⁶ cm/s) in the PAMPA-BBB assay.

	Permeability (<i>Pe</i> , 10 ⁻⁶ cm/s)
Compounds of high BBB permeation (CNS+)	$P_e > 6.2$
Compounds of uncertain BBB permeation (CNS+/-)	$6.2 > P_e > 3.8$
Compounds of low BBB permeation (CNS-)	$P_{e} < 3.8$

REFERENCE

1. Di L, Kerns EH, Fan K, McConnell OJ and Carter GT. High throughput artificial membrane ermeability assay for blood–brain barrier. *Eur J Med Chem*, **2003**. 38: p. 223-232.